Making gene therapy for osteosarcoma a reality

References

• Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin. Orthop. Relat. Res.466(9), 2114–2130 (2008).
   PubMed Web of Science ®Google Scholar
• Guise TA, O’Keefe R, Randall RL, Terek RM. Molecular biology and therapeutics in musculoskeletal oncology. J. Bone Joint Surg. Am.91(3), 724–732 (2009).
   PubMed Web of Science ®Google Scholar
• Tan ML, Choong PF, Dass CR. Osteosarcoma: conventional treatment vs. gene therapy. Cancer Biol. Ther.8(2), 106–117 (2009).
   PubMed Web of Science ®Google Scholar
• Canale ST, Beaty JH. Campbell’s Operative Orthopaedics. Mosby Elsevier, NY, USA (2008).
   Google Scholar
• Dass CR, Choong PF. Gene therapy for osteosarcoma: steps towards clinical studies. J. Pharm. Pharmacol.60(4), 405–413 (2008).
   PubMedGoogle Scholar
• Walkley CR, Qudsi R, Sankaran VG et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev.22(12), 1662–1676 (2008).
   PubMed Web of Science ®Google Scholar
• Paulino AC, Fowler BZ. Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr. Hematol. Oncol.22(2), 89–101 (2005).
   PubMed Web of Science ®Google Scholar
• Libshitz HI, Cohen MA. Radiation-induced osteochondromas. Radiology142(3), 643–647 (1982).
   PubMedGoogle Scholar
• Bovee JV, Sakkers RJ, Geirnaerdt MJ, Taminiau AH, Hogendoorn PC. Intermediate grade osteosarcoma and chondrosarcoma arising in an osteochondroma. A case report of a patient with hereditary multiple exostoses. J. Clin. Pathol.55(3), 226–229 (2002).
   PubMedGoogle Scholar
• Rani AS, Kumar S. Transformation of non-tumorigenic osteoblast-like human osteosarcoma cells by hexavalent chromates: alteration of morphology, induction of anchorage-independence and proteolytic function. Carcinogenesis13(11), 2021–2027 (1992).
   PubMedGoogle Scholar
• Dutra FR, Largent EJ. Osteosarcoma induced by beryllium oxide. Am. J. Pathol.26(2), 197–209 (1950).
   PubMed Web of Science ®Google Scholar
• Mazabraud A. [Experimental production of bone sarcomas in the rabbit by a single local injection of beryllium]. Bulletin du Cancer62(1), 49–58 (1975).
   PubMed Web of Science ®Google Scholar
• Longhi A, Benassi MS, Molendini L, Macchiagodena M, Picci P, Bacci G. Osteosarcoma in blood relatives. Oncol. Rep.8(1), 131–136 (2001).
   PubMedGoogle Scholar
• Iida K, Nobori T, Matsumine A et al. Effect of retinoblastoma tumor suppressor gene expression on chemosensitivity of human osteosarcoma cell lines. Oncol. Rep.10(6), 1961–1965 (2003).
   PubMedGoogle Scholar
• Ternovoi VV, Curiel DT, Smith BF, Siegal GP. Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma. Lab. Invest.86(8), 748–766 (2006).
   PubMed Web of Science ®Google Scholar
• Oshima Y, Sasaki Y, Negishi H et al. Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines. Cancer Biol. Ther.6(7), 1058–1066 (2007).
   PubMed Web of Science ®Google Scholar
• Wu JX, Carpenter PM, Gresens C et al. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene5(7), 989–1000 (1990).
   PubMed Web of Science ®Google Scholar
• Franchi A, Calzolari A, Zampi G. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch.432(6), 515–519 (1998).
   PubMed Web of Science ®Google Scholar
• Beedles KE, Sharpe PT, Wagner EF, Grigoriadis AE. A putative role for c-fos in the pathophysiology of Paget’s disease. J. Bone Miner. Res.14(Suppl. 2), 21–28 (1999).
   PubMedGoogle Scholar
• Wang ZQ, Liang J, Schellander K, Wagner EF, Grigoriadis AE. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res.55(24), 6244–6251 (1995).
   PubMedGoogle Scholar
• Dass CR, Friedhuber AM, Khachigian LM, Dunstan DE, Choong PF. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. J. Microencapsul.25(6), 421–425 (2008).
   PubMed Web of Science ®Google Scholar
• Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit. Rev. Oncol. Hematol.46(2), 165–186 (2003).
   PubMed Web of Science ®Google Scholar
• Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol. Med.10(5), 201–204 (2004).
   PubMed Web of Science ®Google Scholar
• Khanna C, Wan X, Bose S et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med.10(2), 182–186 (2004).
   PubMed Web of Science ®Google Scholar
• Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin. Orthop. Relat. Res. (415 Suppl.), S46–S58 (2003).
   Google Scholar
• Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol.25(1), 33–39 (2007).
   PubMed Web of Science ®Google Scholar
• Choong PF, Fernö M, Akerman M et al. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int. J. Cancer69(4), 268–272 (1996).
   PubMed Web of Science ®Google Scholar
• Dass CR, Nadesapillai AP, Robin D et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin. Exp. Metastasis22(8), 643–652 (2005).
   PubMed Web of Science ®Google Scholar
• Dass CR, Choong PF. uPAR mediates anticancer activity of PEDF. Cancer Biol. Ther.7(8), 1262–1270 (2008).
   PubMed Web of Science ®Google Scholar
• Ek ET, Dass CR, Choong PF. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol. Med.12(10), 497–502 (2006).
   PubMed Web of Science ®Google Scholar
• Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther.14(7), 616–626 (2007).
   PubMed Web of Science ®Google Scholar
• Ta HT, Dass CR, Larson I, Choong PF, Dunstan DE. A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. Biomaterials30(27), 4815–4823 (2009).
   PubMed Web of Science ®Google Scholar
• Tack F, Bakker A, Maes S et al. Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). J. Drug Target14(2), 69–86 (2006).
   PubMed Web of Science ®Google Scholar
• Kaiser J. Clinical trials. Gene transfer an unlikely contributor to patient’s death. Science318(5856), 1535 (2007).
   PubMed Web of Science ®Google Scholar
• Kaiser J. Gene therapy. Questions remain on cause of death in arthritis trial. Science317(5845), 1665 (2007).
   PubMedGoogle Scholar
• Kaiser J. Clinical research. Death prompts a review of gene therapy vector. Science317(5838), 580 (2007).
   PubMed Web of Science ®Google Scholar
• Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res.132(1–2), 1–14 (2008).
   PubMed Web of Science ®Google Scholar
• Thrasher AJ, Gaspar HB, Baum C et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature443(7109), E5–6 (2006).
   Web of Science ®Google Scholar
• Kaiser J. Gene therapy. Panel urges limits on X-SCID trials. Science307(5715), 1544–1545 (2005).
   PubMedGoogle Scholar
• Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol. Ther.4(5), 512–517 (2005).
   PubMed Web of Science ®Google Scholar
• Sharma A, Li X, Bangari DS, Mittal SK. Adenovirus receptors and their implications in gene delivery. Virus Res.143(2), 184–194 (2009).
   PubMed Web of Science ®Google Scholar
• Carette JE, Graat HC, Schagen FH et al. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology361(1), 56–67 (2007).
   PubMedGoogle Scholar
• Barnett BG, Tillman BW, Curiel DT, Douglas JT. Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol. Ther.6(3), 377–385 (2002).
   PubMedGoogle Scholar
• Murofushi Y, Nagano S, Kamizono J et al. Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerase-dependent targeted cancer gene therapy. Int. J. Oncol.29(3), 681–688 (2006).
   PubMed Web of Science ®Google Scholar
• Dass CR, Choong PF. Non-viral methods for gene transfer towards osteosarcoma therapy. J. Drug Target15(3), 184–189 (2007).
   PubMed Web of Science ®Google Scholar
• Ek ET, Choong PF. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev. Anticancer Ther.6(2), 225–237 (2006).
   PubMed Web of Science ®Google Scholar
• Worth LL, Jia SF, Zhou Z, Chen L, Kleinerman ES. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin. Cancer Res.6(9), 3713–3718 (2000).
   PubMed Web of Science ®Google Scholar
• Densmore CL, Kleinerman ES, Gautam A et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI–p53 complexes. Cancer Gene Ther.8(9), 619–627 (2001).
   PubMed Web of Science ®Google Scholar
• Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther.9(3), 260–266 (2002).
   PubMed Web of Science ®Google Scholar
• Jia SF, Worth LL, Densmore CL, Xu B, Duan X, Kleinerman ES. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin. Cancer Res.9(9), 3462–3468 (2003).
   PubMed Web of Science ®Google Scholar
• Duan X, Jia SF, Koshkina N, Kleinerman ES. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer106(6), 1382–1388 (2006).
   PubMed Web of Science ®Google Scholar
• Ta HT, Dass CR, Dunstan DE. Injectable chitosan hydrogels for localised cancer therapy. J. Control Release126(3), 205–216 (2008).
   PubMed Web of Science ®Google Scholar